21.91  -3.84 (-14.91%)		01-30 16:00
Open: 23.97 High: 24.5582 Volume: 81,177		Pre. Close: 25.75 Low: 20.0001 Market Cap: 962(M)

Short term
Mid term
Targets	6-month :	39.29	1-year :	50.22
Resists	First :	33.64	Second :	43
Pivot price	30.15
Supports	First :	18.5	Second :	15.39
MAs	MA(5) :	22.22	MA(20) :	30.74
	MA(100) :	30.15	MA(250) :	0
MACD	MACD :	-2.4	Signal :	-1
%K %D	K(14,3) :	15.5	D(3) :	12.1
RSI	RSI(14): 40.4
52-week	High :	55.65	Low :	5.32

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NNNN ] has closed above bottom band by 18.2%. Bollinger Bands are 75.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	24.63 - 24.76	24.76 - 24.88
Low:	19.65 - 19.81	19.81 - 19.94
Close:	21.65 - 21.91	21.91 - 22.12

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Thu, 20 Feb 2025
Anbio Biotechnology Closes Initial Public Offering, Raising $8 Million on Nasdaq - Nasdaq

Wed, 19 Feb 2025
Anbio Biotechnology’s IPO opens up 5% By Investing.com - Investing.com Canada

Tue, 18 Feb 2025
NNNN - ANBIO BIOTECHNOLOGY Latest Stock News & Market Updates - Stock Titan

Tue, 18 Feb 2025
NNNN Stock Price and Chart — NASDAQ:NNNN - TradingView

Thu, 02 Jan 2025
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch - Seeking Alpha

Mon, 02 Feb 2026

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	44 (M)
Shares Float	40 (M)
Held by Insiders	4.7 (%)
Held by Institutions	4.9 (%)
Shares Short	47 (K)
Shares Short P.Month	59 (K)

EPS	0.05
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.62
Profit Margin	37.2 %
Operating Margin	73.4 %
Return on Assets (ttm)	4.7 %
Return on Equity (ttm)	11.1 %
Qtrly Rev. Growth	-21.7 %
Gross Profit (p.s.)	0.14
Sales Per Share	0.15
EBITDA (p.s.)	0
Qtrly Earnings Growth	2.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	365.16
PEG Ratio	0
Price to Book value	34.77
Price to Sales	138.96
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.